Abstract: A vehicle for topical application which contains a liquid eutectic mixture of hydrophobic compounds to improve solubility of pharmaceutically active component and enhance topical and transdermal delivery.

Abstract: Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Abstract: Provided is a set of two or more mass labels, each label in the set comprising a mass marker moiety attached via a cleavable linker having at least one amide bond to a mass normalisation moiety, wherein the aggregate mass of each label in the set may be the same or different and the mass of the mass marker moiety of each label in the set may be the same or different, and wherein in any group of labels within the set having a mass marker moiety of a common mass each label has an aggregate mass different from all other labels in that group, and wherein in any group of labels within the set having a common aggregate mass each label has a mass marker moiety having a mass different from that of all other mass marker moieties in that group, such that all of the mass labels in the set are distinguishable from each other by mass spectromety, and wherein the mass marker moiety comprises an amino acid and the mass normalisation moiety comprises an amino acid.

Abstract: A delivery method and product for enhancing the bioavailability of an active ingredient by prolonged relatively constant release. The method involves mixing with subsequent granulation and compression of a mixture to result in a solid core tablet. The composition includes a biologically active material matrixed or otherwise contained within a hydrophobic phase with the latter absorbed onto a sorbent. The sorbent and hydrophobic phase are in a ratio of between 1:10 and 10:1. The mixture further includes a pharmaceutically acceptable surfactant. The composition, once tableted into a solid core provides spontaneous release of the biologically active material over a predetermined time frame for substantially constant bioavailability.

Abstract: Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Abstract: Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Abstract: A vehicle for topical delivery which contains a liquid eutectic mixture of hydrophobic compounds.

Abstract: Compositions and methods of stabilizing azithromycin compositions are described. Stabilized azithromycin compositions comprise an intimate admixture of azithromycin and a stabilizing-effective amount of an antioxidant to improve the resistance of the azithromycin to degradation. Coprecipitation or co-milling of azithromycin and an antioxidant are particularly preferred means of achieving an intimate admixture. Pharmaceutical formulations comprising a stabilized azithromycin composition and methods of making such formulations are also described.

Abstract: A delivery method and product for enhancing the bioavailability of an active ingredient by prolonged relatively constant release. The method involves mixing with subsequent granulation and compression of a mixture to result in a solid core tablet. The composition includes a biologically active material matrixed or otherwise contained within a hydrophobic phase with the latter absorbed onto a sorbent. The sorbent and hydrophobic phase are in a ratio of between 1:10 and 10:1. The mixture further includes a pharmaceutically acceptable surfactant. The composition, once tableted into a solid core provides spontaneous release of the biologically active material over a predetermined time frame for substantially constant bioavailability.

Abstract: A composition for a method of sustained delivery of a biologically active material. The composition provides a biologically active material in a pharmaceutically acceptable hydrophobic phase for mixture with the biologically active material. An emulsifier emulsifies the hydrophobic phase in water for the mixture. The composition further includes a sorbent and a water absorbent polymer, the latter providing sustained release of the biologically active material in the emulsion.

Abstract: Toothpaste incorporating chlorhexidine bigluconate for improved adhesive onto the surface of the teeth. A second embodiment discusses the use of triclosan and in combination with sodium monofluorphosphate for use in the toothpaste.

Abstract: The invention relates to novel methods for making oil-in-water emulsions having mucoadhesive properties which are primarily intended for administration of biologically active compounds to mucosal surfaces. The emulsion has an aqueous continuous phase and a plurality of submicron particles having an average particle diameter of from 10 nm to 600 nm, with the particles having a hydrophobic phase of a fat or oil which forms a hydrophobic core that is surrounded by a surfactant layer. The emulsion further includes a mucoadhesive polymer which is a polymer or copolymer of acrylic acid or methacrylic acid, a poly (methyl vinyl ether/maleic anhydride) copolymer, pectin, alginic acid, hyaluronic acid, chitosan, gum tragacanth, karaya gum or carboxymethylcellulose surrounding the hydrophobic one. A biologically active compound may also be included, if desired.

Abstract: The present invention provides emulsions comprising a plurality of submicron particles, a bioactive peptide, and an aqueous continuous phase or that effect enhanced oral bioavailability of the peptide. Another aspect of the invention provides compositions and methods of administering peptides in an emulsion comprising a plurality of submicron particles, a mucoadhesive macromolecule, a bioactive peptide, and an aqueous continuous phase, which promotes absorption of the bioactive peptide through mucosal surfaces by achieving mucoadhesion of the emulsion particles. Mucous surfaces suitable for application of the emulsions of the present invention may include corneal, conjunctival, buccal, sublingual, nasal, vaginal, pulmonary, stomachic, intestinal, and rectal routes of administration.